A method for treating skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Sequoia sempervirens, Geranium oil, panthenol, citric acid, and glycerin, wherein the composition increases antioxidant activity in the skin and/or increases skin moisture content.

A pharmaceutical composition for preventing or treating hyperlipidemia includes a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract, thereby reducing the amounts of serum cholesterol and LDL-cholesterol and increasing the amount of HDL-cholesterol; significantly reduces the amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduces the amounts of hepatic cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

A pharmaceutical composition for preventing or treating hyperlipidemia includes a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract, thereby reducing the amounts of serum cholesterol and LDL-cholesterol and increasing the amount of HDL-cholesterol; significantly reduces the amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduces the amounts of hepatic cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

A pharmaceutical composition for preventing or treating hyperlipidemia includes a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract, thereby reducing the amounts of serum cholesterol and LDL-cholesterol and increasing the amount of HDL-cholesterol; significantly reduces the amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduces the amounts of hepatic cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.

This application pertains generally to nutritional supplements comprising organic nutrients for consumption by a mammalian subject that supports and protects the immune system in a synergistic and complex way.

This application pertains generally to nutritional supplements comprising organic nutrients for consumption by a mammalian subject that supports and protects the immune system in a synergistic and complex way.

This application pertains generally to nutritional supplements comprising organic nutrients for consumption by a mammalian subject that supports and protects the immune system in a synergistic and complex way.

The present disclosure relates to methods of administering a compound for treating a patient suffering from thyroid disease and various thyroid-related disorders, including hyperthyroid and hypothyroid. The composition is preferably comprised of at least selenium, zinc, iodine, manganese, molybdenum, ashwaganda root powder, polygonum root extract, a digestive enzyme such as DPP-IV, L-tyrosine and mullein leaf, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule or tablet.

The present disclosure relates to methods of administering a compound for treating a patient suffering from thyroid disease and various thyroid-related disorders, including hyperthyroid and hypothyroid. The composition is preferably comprised of at least selenium, zinc, iodine, manganese, molybdenum, ashwaganda root powder, polygonum root extract, a digestive enzyme such as DPP-IV, L-tyrosine and mullein leaf, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule or tablet.

The present disclosure relates to methods of administering a compound for treating a patient suffering from thyroid disease and various thyroid-related disorders, including hyperthyroid and hypothyroid. The composition is preferably comprised of at least selenium, zinc, iodine, manganese, molybdenum, ashwaganda root powder, polygonum root extract, a digestive enzyme such as DPP-IV, L-tyrosine and mullein leaf, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule or tablet.